ONCOMPASS™ Full is a premier molecular diagnostic and therapeutic information service. It includes: A cutting edge molecular diagnostic of up to 60 therapeutically relevant genes from the tumor, using next generation sequencing methods. For improved quality information at least three FISH analyses of selected genes are also carried out.
ONCOMPASS™ Calculator reveals which targeted therapy has a positive or negative association with the individual mutation profile of the patient, based on the findings of relevant scientific publications. The Calculator reports whether an effective drug is registered for the patient’s tumor type or only available off label or in clinical trials. It also discloses which compound is not likely to be effective in the fight against the particular tumor. A list of globally available clinical trials that might benefit the patient.
ONCOMPASS™ Full tests the following genes:
ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL,DDR2, CHEK2, PIK3R1, MAP2K1, JAK1, TGFBR2, PDGFRB, IGFR1, and and up to 6 FISH tests – recommended by Oncompass – from the followings: HER-2, ALK, c-MET, FGFR1, PIK3CA, EGFR, ROS-1.